NVIV
-34.28%(-0.17)
Open
0.41
Prev Close
0.49
Day High
0.41
Day Low
0.30
Volume
1.6M
Avg Volume
3.8M
52W High
2.40
52W Low
0.22
ANALYST COVERAGE3 analysts
BUY
Buy
3100%
3 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
PRICE
Prev Close
0.49
Open
0.41
Day Range0.30 – 0.41
0.30
0.41
52W Range0.22 – 2.40
0.22
2.40
5% of range
VOLUME & SIZE
Avg Volume
3.8M
FUNDAMENTALS
P/E Ratio
-0.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.95
Market-like
TECHNICAL
RSI (14)
38
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 108 days
Sep 8

NVIV News

About

about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi

Industry
Surgical and Medical Instrument Manufacturing
CEO
Richard Toselli
Joseph Philip VacantiCo-Founder
Richard ToselliPresident, Chief Executive Officer, Chief Medical Officer & Director
Robert S. Langer Jr.Co-Founder & Member of Scientific Advisory Board
Richard C. ChristopherChief Financial Officer & Treasurer
Heather HamelChief Legal Officer & General Counsel